Cosette Pharmaceuticals Buys Assertio Holdings Product Portfolio

Bridgewater-based Cosette Pharmaceuticals has agreed to buy the U.S. sales and distribution rights for a portfolio of seven branded products from Assertio Holdings Inc., the company announced April 9. Financial terms were not disclosed.

The deal is a meaningful expansion for Cosette, a specialty pharma company with about 350 employees backed by private equity firm Avista Healthcare Partners and investment manager Hamilton Lane. The acquisition adds six branded non-steroidal anti-inflammatory drugs to its portfolio, covering inflammation, pain management and migraine treatment. But the centerpiece is SYMPAZAN.

SYMPAZAN is the only FDA-approved oral film formulation of clobazam, a drug used to treat seizures tied to Lennox-Gastaut Syndrome, a rare and severe form of epilepsy. It’s approved for patients as young as 2. LGS accounts for 1 to 10 percent of childhood epilepsies and 1 to 2 percent of all epilepsy cases, so the patient population is small but the unmet need is significant. Patent protection runs until 2040, which gives Cosette a long runway on a product with no direct equivalent on the market. Not nothing.

“This acquisition reflects Cosette’s strategic approach to expanding our branded portfolio,” said Apurva Saraf, president and CEO of Cosette Pharmaceuticals. “It adds immediate scale through branded, on-market products and includes SYMPAZAN.”

Saraf called the deal evidence of Cosette’s ability to “execute strategic transactions propelling our growth.”

The six other products acquired from Assertio are INDOCIN (indomethacin) in both oral and suppository form, SPRIX (ketorolac tromethamine) nasal spray, ZIPSOR (diclofenac potassium) liquid-filled capsules, CAMBIA (diclofenac potassium) oral solution, and OTREXUP (methotrexate) injection for subcutaneous use. These are established drugs. Familiar names to anyone who has spent time in a rheumatology or pain management practice, which, given Cosette’s pharma-heavy Bridgewater ZIP code, probably describes a fair number of people within a few miles of the company’s offices.

The agreement includes a transition period during which Assertio and Cosette will hand off manufacturing, supply and commercial responsibilities, including quality assurance, pharmacovigilance and regulatory matters. That kind of transition is standard in specialty pharma acquisitions, but it’s worth watching. These handoffs can get bumpy, particularly when pharmacovigilance systems don’t talk to each other cleanly or when field sales teams are juggling new product training mid-year.

For Cosette’s roughly 350 employees, the deal presumably means more products to carry, which usually signals commercial team growth rather than cuts. The company didn’t announce any workforce changes. Still, integration periods are where things get uncertain, and workers in sales, medical affairs and regulatory roles at both companies will be paying close attention as responsibilities shift.

The broader picture here is that Cosette is building out two distinct therapeutic lanes, pain and inflammation on one side, rare neurology on the other, with SYMPAZAN planting the flag on that second track. Rare disease has become an increasingly attractive corner of pharma because the patient populations are small but the pricing power tends to be substantial and the competition thinner. A patent-protected asset with exclusivity stretching to 2040 fits that calculus neatly.

Assertio Holdings, for its part, is selling off a portfolio of on-market products. That kind of divestiture typically signals a company streamlining toward a different focus, though Assertio did not detail its rationale publicly in connection with this deal.

The original report on this transaction was published by ROI-NJ.

Cosette joins a long list of pharma companies anchored along the Route 1 corridor and in Somerset County that have been quietly expanding through acquisition rather than internal pipeline development. It’s a different model than the blockbuster-drug bet, but for a mid-sized specialty company with private equity backing, buying proven revenue is often faster and cleaner than growing it from scratch. Whether SYMPAZAN becomes the neurology foothold Saraf is describing, or just one more branded product in a crowded specialty catalog, depends on what the commercial team does with it now.